PureTech’s Failure Leaves Long COVID Treatment Hopes Looking Thin
But Candidate Promising In IPF
PureTech’s LYT-100 has failed to show benefit over placebo in long COVID, and raised doubts about how treatable the condition is – in contrast to the drug’s other potential use in idiopathic pulmonary fibrosis.
You may also be interested in...
CytoDyn In Damage-Control Mode (Again) With Clinical Holds For Leronlimab
Troubled leronlimab is placed on partial clinical hold in HIV, full clinical hold in COVID-19. While searching for a new CEO, CytoDyn tries to reassure investors about its business plan going forward.
Where To Start Tackling ‘Long Covid’? PureTech Pioneers Lung Drug Trial
PureTech is among the very first companies to attempt to treat long Covid and hopes its anti-fibrosis drug can aid patients’ recovery
Antibody-Drug Conjugates Take Their Place On The ASCO 2023 Stage
Investment from big and small players against existing and novel targets is making antibody-drug conjugates one of the fastest-growing fields in oncology, as attested by their presence at the upcoming ASCO meeting.